Decreased progesterone receptor isoform expression in luteal phase fallopian tube epithelium and high-grade serous carcinoma.
We previously reported that BRCA1/2-mutated fallopian tube epithelium (FTE) collected during the luteal phase exhibits gene expression profiles more closely resembling that of high-grade serous carcinoma (HGSC) specimens than FTE collected during the follicular phase or from control patients. Since the luteal phase is characterised by high levels of progesterone, we determined whether the expression of progesterone receptor (PR) and PR-responsive genes was altered in FTE obtained from BRCA mutation carriers during the luteal phase of the menstrual cycle. RT-qPCR confirmed a decreased expression of PR mRNA in FTE during the luteal phase relative to follicular phase, in both BRCA1/2 mutation carriers and control patients. Immunohistochemistry using isoform-specific antibodies confirmed a low level of both PR-A and PR-B in HGSC and a lower level of staining in FTE samples obtained during the luteal phase compared with the follicular phase. No significant difference in PR-A or PR-B staining was found based on patient BRCA mutation status. Analysis of our previously reported gene expression profiles based upon known PR-A- and PR-B-specific target genes did not partition samples by BRCA mutation status, indicating that overall FTE PR response is not altered in BRCA mutation carriers. HGSC samples grouped separately from other samples, consistent with the observed loss of PR expression. These findings indicate no overall difference in PR signalling in FTE as a function of BRCA mutation status. Thus, the molecular similarity of BRCA1/2-mutated luteal phase FTE and HGSC likely results from an altered response to luteal phase factors other than progesterone.
The Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada M5G 1L4.
Alicia A
AA
Tone
Carl
C
Virtanen
Patricia A
PA
Shaw
Theodore J
TJ
Brown
D018284:Cystadenocarcinoma, Serous / Q000378:metabolism*; D004848:Epithelium / Q000378:metabolism; D005187:Fallopian Tubes / Q000378:metabolism*; D005260:Female; D020869:Gene Expression Profiling; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D020022:Genetic Predisposition to Disease; D006801:Humans; D007150:Immunohistochemistry; D008183:Luteal Phase / Q000378:metabolism*; D020033:Protein Isoforms / Q000235:genetics / Q000378:metabolism; D012333:RNA, Messenger / Q000737:chemistry / Q000235:genetics; D011980:Receptors, Progesterone / Q000235:genetics / Q000378:metabolism*; D020133:Reverse Transcriptase Polymerase Chain Reaction
D020033:Protein Isoforms; D012333:RNA, Messenger; D011980:Receptors, Progesterone
Cancer Res. 2002 Jan 1;62(1):141-51
11782371
Gynecol Oncol. 2006 Jan;100(1):58-64
16137750
Clin Cancer Res. 1995 Sep;1(9):945-53
9816065
Int J Fertil. 1987 Mar-Apr;32(2):162-6
2883146
Cancer Res. 1995 Nov 1;55(21):5063-8
7585552
Clin Cancer Res. 2008 Jul 1;14(13):4067-78
18593983
Histopathology. 2003 Jul;43(1):26-32
12823709
J Clin Pathol. 2001 Aug;54(8):624-30
11477119
Curr Opin Obstet Gynecol. 2007 Feb;19(1):3-9
17218844
Mol Cell Biol. 2004 Dec;24(24):10542-57
15572662
Am J Pathol. 2004 May;164(5):1511-8
15111296
Jpn J Cancer Res. 2002 Jul;93(7):807-15
12149147
Obstet Gynecol. 2005 Dec;106(6):1327-34
16319259
Science. 1990 Dec 21;250(4988):1740-3
2176746
Am J Surg Pathol. 2007 Feb;31(2):161-9
17255760
Hum Reprod. 1994 Dec;9(12):2224-33
7714136
Virchows Arch A Pathol Anat Histol. 1982;397(3):363-8
7157670
Mol Endocrinol. 2006 Jan;20(1):14-34
16109739
J Pathol. 2001 Nov;195(4):451-6
11745677
J Assist Reprod Genet. 2005 Dec;22(11-12):429-35
16331541
Am J Surg Pathol. 2006 Feb;30(2):230-6
16434898
Proc Natl Acad Sci U S A. 1999 May 11;96(10):5722-7
10318951
Breast Cancer Res Treat. 2002 Mar;72(2):163-72
12038707
J Clin Endocrinol Metab. 1980 Oct;51(4):776-80
7191430
Steroids. 2003 Nov;68(10-13):761-70
14667966
Steroids. 2008 Oct;73(9-10):922-8
18321550
Proc Natl Acad Sci U S A. 2002 May 14;99(10):6567-72
12011421
Proc Natl Acad Sci U S A. 2000 Feb 1;97(3):1032-7
10655479
Mol Endocrinol. 1993 Oct;7(10):1244-55
8264658
Gynecol Oncol. 1998 Nov;71(2):299-304
9826475
Am J Pathol. 2002 Apr;160(4):1223-8
11943707
Am J Physiol Endocrinol Metab. 2006 Jul;291(1):E59-72
16449295
Int J Cancer. 2008 Jan 1;122(1):230-43
17893877
Reproduction. 2004 Aug;128(2):139-46
15280552
Br J Cancer. 2000 Dec;83(11):1488-94
11076658
Gynecol Oncol. 2008 May;109(2):168-73
18342932
Am J Surg Pathol. 2001 Oct;25(10):1283-9
11688463
Jpn J Cancer Res. 2001 Mar;92(3):302-8
11267940
Gynecol Oncol. 2005 Mar;96(3):671-7
15721410
Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9587-92
11493692
J Pathol. 2007 Jan;211(1):26-35
17117391
Gynecol Oncol. 2005 Apr;97(1):16-25
15790432
Hum Reprod Update. 2009 Jan-Feb;15(1):119-38
18936037
Mol Endocrinol. 2005 Mar;19(3):574-87
15563544
J Reprod Fertil. 1984 Mar;70(2):481-5
6538232
Mod Pathol. 2009 Sep;22(9):1133-8
19543244
Genes Chromosomes Cancer. 2004 Mar;39(3):236-48
14732925
Gynecol Oncol. 2010 Apr;117(1):9-17
20117829